v3.26.1
STOCKHOLDERS' EQUITY (Tables)
3 Months Ended
Mar. 31, 2026
STOCKHOLDERS' EQUITY  
Schedule of designation, shares authorized, and shares outstanding for the Company's Preferred Stock

Preferred Shares

Preferred Shares

Potentially Issuable

Preferred Stock Series Designation

  ​ ​ ​

Authorized

  ​ ​ ​

Outstanding

  ​ ​ ​

Preferred Shares

Series Seed

213,000,000

204,772,940

8,227,060

Series A

207,000,000

185,440,880

21,559,120

Series T

99,000,000

9,642,080

89,357,920

Schedule of inputs valued under using the Black-Scholes pricing model

  ​ ​ ​

2026

  ​ ​ ​

Expected life (years)

 

6.5

 

Risk-free interest rate

 

4.0

%  

Expected volatility

 

54.6

%  

Annual dividend yield

 

0

%  

Schedule of stock option activity and related information

Options

  ​ ​

Weighted- Average Exercise Price

  ​ ​

Aggregate Intrinsic Value

Outstanding at December 31, 2025

158,828,223

0.59

-

Granted

12,410,000

1.60

-

Exercised

(38,077)

0.22

52,673

Forfeited

(2,543,846)

1.20

-

Expired

-

-

-

Outstanding at March 31, 2026

168,656,300

0.67

(156,285,428)

Exercisable at March 31, 2026

110,533,808

0.46

(126,008,541)

Schedule of stock option expense

Three Months Ended March 31, 

 

2026

  ​ ​ ​

2025

Cost of revenues

$

428,741

$

300,583

General and administrative

 

520,273

 

486,966

Sales and marketing

 

1,372,776

 

1,374,978

Research and development

 

516,477

 

488,553

Total

$

2,838,267

$

2,651,080